Butterfly Pea Flower (Clitoria Ternatea) for Adjuvant TB Treatment

Early Phase 1

Completed

• Conditions: Tuberculosis (TB); Tuberculosis Treatment Effectiveness
• Interventions: Drug: Herbal medicine; Other: Tuberculosis (TB) treatment

• Registration Number: NCT06794502
• Lead Sponsor: Universitas Muhammadiyah Semarang

Brief Summary

The goal of this clinical trial is to learn if butterfly pea flowers (Clitoria ternatea) decocta extract works to treat as adjuvant therapy for tuberculosis in adults. It will also learn about the safety of butterfly pea flowers decocta extract.

The main questions it aims to answer are:

* Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the profiles of interferon gamma and interleukin-10 of people with tuberculosis?

* Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the hematology profiles of people with tuberculosis?

* Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the clinical symptoms and acid-fast bacilli microscopic analysis of people with tuberculosis?

* What medical problems do participants have when taking butterfly pea flower decocta extracts?

Researchers will compare butterfly pea flower extract as an adjunct TB drug therapy to monotherapy TB drugs to see if adjuvant butterfly pea flowers extract works to treat tuberculosis infection in 2-month initiation phase therapy.

Participants will:

* Take drug butterfly pea flower extract plus TB regimen drugs consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol or monotherapy TB regimen drugs only every day for 2 months

* Willing to undergo treatment monitoring and visit the clinic once every 2 weeks for checkups and tests

* Keep a diary of their symptoms and the number of times they use a butterfly pea flower decocta extract

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-14
• Primary Completion: 2024-06-30
• Study Completion: 2024-08-31
• Status Verified: 2025-01
• Study First Submitted: 2025-01-20
• Study First Submitted QC: 2025-01-20
• Last Update Submitted: 2025-01-20
• Study First Posted: 2025-01-27
• Last Update Posted: 2025-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Pulmonary TB patients were positive based on the results of the Rapid Molecular Test GeneXpert M. tuberculosis (MTB)/Rifampicin (RIF),
• Patients who were undergoing the initiation phase of anti-TB treatment for the first time,
• Non-Multi Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) TB patients with first-line anti-TB treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol),
• Patients >18 years old,
• Patients who were willing to become research subjects and signed informed consent.

Exclusion Criteria

• TB patients with Human Immunodeficiency Virus (HIV) positive,
• Patients who did not complete the study,
• Patients with non-compliance in taking medication,
• Patients with comorbidities (autoimmune and cancer),
• Smoking patients,
• Patients contraindicated in using butterfly pea flower extract.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Butterfly pea flower extract and anti-TB regimens	Herbal medicine	The adjuvant therapy group of Tuberculosis patients (Group 1) were given an herbal medicine butterfly pea flower extract of 40 mL/day and anti-TB regimen for 2 months.
Anti-TB regimens monotherapy	Tuberculosis (TB) treatment	The patients in anti-TB monotherapy group (Group 2) were given a regimen consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months.

Primary Outcome Measures

Name	Time	Method
The interferon-gamma and interleukin-10 cytokines	From enrollment to the end of treatment at 2 months	Evaluation of the success of anti-TB therapy and anti-TB plus adjuvant butterfly pea flower therapy was carried out after completion of the 2-month initiation phase of treatment. Change Factor Analysis (CFA) for each cytokines parameter (interferon gamma or interleukin 10) was compared between the two treatment groups. Change Factor Analysis (CFA) for each therapy group was used to see whether there was an increase or decrease in cytokine concentrations after 2 months of therapy. The value was calculated from the concentration of each cytokine after treatment minus the concentration before treatment and divided by the concentration before treatment. After obtaining the CFA value for each group, the results between the groups were compared using independent t-test analysis.
Hematology profiles	From enrollment to the end of treatment at 2 months	For hematological profile analysis, the Change Factor Analysis (CFA) for each parameter, namely Hb (g/dL), leukocytes and platelets (cells/µL), hematocrit and granulocytes (%), and Erythrocyte Sedimentation Rate (ESR) (mm/hour) was calculated for each treatment group. Change Factor Analysis (CFA) in each therapy group was used to see whether there was an increase or decrease in the concentration of each hematological parameter after 2 months of therapy. This CFA value is calculated from the concentration of each hematological profile after treatment minus the concentration before treatment and divided by the concentration before treatment. After obtaining the CFA value for each hematology parameter in each group, the results between butterfly pea flower extract plus anti TB-regimen groups and monotherapy anti-TB regimen were compared using independent t test analysis.
Microscopic profiles of acid-fast bacilli (AFBs)	From enrollment to the end of treatment at 2 months	Microscopic analysis of Mycobacterium tuberculosis was carried out using Ziehl-Nielsen staining of sputum from TB patients in all therapy groups. Microscopic examination was carried out before and after treatment. The results of the examination are evaluated descriptively by seeing whether there is a decrease in the positive value of the number of colonies found during the examination.

Trial Locations

Locations (2)

West Kotawaringin Health Department; 🇮🇩 Pangkalan Bun, Central Kalimantan, Indonesia

Mendawai Community Health Center; 🇮🇩 Pangkalan Bun, Central Kalimantan, Indonesia